The EMERALD trial demonstrated the efficacy of elacestrant, a novel oral SERD, in patients with ER-positive, HER2-negative advanced breast cancer who had progressed after prior endocrine therapy and CDK4/6 inhibitors. The gene discussed is CDK4; the disease is breast carcinoma.